NCT03809780View on ClinicalTrials.gov

Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide

-high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]

DRUG

Dexamethasone

-high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]

Trial Locations (1)

49267

Kosin University Gospel Hospital, Busan

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Kosin University Gospel Hospital

OTHER

NCT03809780 - Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone | Biotech Hunter | Biotech Hunter